Notice: This company has been marked as potentially delisted and may not be actively trading. TRACON Pharmaceuticals (TCON) Insider Trading & Ownership Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsDividendEarningsHeadlinesInsider TradesTrendsBuy This Stock TRACON Pharmaceuticals (NASDAQ:TCON) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage5.27%Number OfInsiders Buying(Last 3 Years)3Amount OfInsider Buying(Last 3 Years)$2.02 MNumber OfInsiders Selling(Last 3 Years)1Amount OfInsider Selling(Last 3 Years)$2,188.80 Get TCON Insider Trade Alerts Want to know when executives and insiders are buying or selling TRACON Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address TCON Insider Buying and Selling by Quarter Remove Ads TRACON Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails4/26/2023Charles TheuerCEOBuy199$13.20$2,626.80 3/9/2023Opaleye Management Inc.Major ShareholderBuy8,725$27.60$240,810.00 2/28/2023Charles TheuerCEOBuy10$30.40$304.00 1/18/2023Charles TheuerCEOBuy340$32.40$11,016.00 12/14/2022Charles TheuerCEOBuy1,150$25.80$29,670.00 12/14/2022Opaleye Management Inc.Major ShareholderBuy8,375$25.00$209,375.00 12/6/2022Opaleye Management Inc.Major ShareholderSell76$28.80$2,188.80 11/18/2022Charles TheuerCEOBuy695$28.20$19,599.00 11/2/2022Charles TheuerCEOBuy300$31.80$9,540.00 10/18/2022Opaleye Management Inc.Major ShareholderBuy625$33.00$20,625.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 10/7/2022Charles TheuerCEOBuy250$35.40$8,850.00 10/3/2022Charles TheuerCEOBuy250$33.40$8,350.00 9/29/2022Opaleye Management Inc.Major ShareholderBuy470$34.80$16,356.00 9/27/2022Opaleye Management Inc.Major ShareholderBuy85$33.80$2,873.00 9/22/2022Charles TheuerCEOBuy250$35.20$8,800.00 9/22/2022Opaleye Management Inc.Major ShareholderBuy865$34.60$29,929.00 9/19/2022Opaleye Management Inc.Major ShareholderBuy250$37.40$9,350.00 9/12/2022Scott B BrownCFOBuy125$40.40$5,050.00 7/26/2022Opaleye Management Inc.Major ShareholderBuy112$34.40$3,852.80 7/22/2022Charles TheuerCEOBuy225$37.00$8,325.00 7/14/2022Opaleye Management Inc.Major ShareholderBuy359$36.20$12,995.80 7/12/2022Charles TheuerCEOBuy150$37.40$5,610.00 6/24/2022Opaleye Management Inc.Major ShareholderBuy570$27.80$15,846.00 6/21/2022Opaleye Management Inc.Major ShareholderBuy42,099$26.20$1,102,993.80 5/10/2022Opaleye Management Inc.Major ShareholderBuy485$35.20$17,072.00 5/9/2022Charles TheuerCEOBuy500$37.00$18,500.00 5/6/2022Charles TheuerCEOBuy125$39.40$4,925.00 4/29/2022Charles TheuerCEOBuy250$39.40$9,850.00 4/25/2022Opaleye Management Inc.Major ShareholderBuy538$43.60$23,456.80 4/22/2022Opaleye Management Inc.Major ShareholderBuy2,100$44.80$94,080.00 4/21/2022Charles TheuerCEOBuy225$46.00$10,350.00 4/13/2022Opaleye Management Inc.Major ShareholderBuy367$50.00$18,350.00 4/11/2022Opaleye Management Inc.Major ShareholderBuy455$48.40$22,022.00 4/8/2022Charles TheuerCEOBuy100$50.00$5,000.00 3/30/2022Charles TheuerCEOBuy200$54.00$10,800.00 (Data available from 1/1/2013 forward) TCON Insider Trading Activity - Frequently Asked Questions Who is on TRACON Pharmaceuticals's Insider Roster? The list of insiders at TRACON Pharmaceuticals includes Charles Theuer, Opaleye Management Inc., and Scott B Brown. Learn more on insiders at TCON. What percentage of TRACON Pharmaceuticals stock is owned by insiders? 5.27% of TRACON Pharmaceuticals stock is owned by insiders. Learn more on TCON's insider holdings. Which TRACON Pharmaceuticals insiders have been buying company stock? The following insider purchased TCON shares in the last 24 months: Charles Theuer ($2,626.80). How much insider buying is happening at TRACON Pharmaceuticals? Insiders have purchased a total of 199 TCON shares in the last 24 months for a total of $2,626.80 bought. TRACON Pharmaceuticals Key ExecutivesDr. Charles P. Theuer M.D. (Age 60)Ph.D., Chairman, CEO & President Compensation: $646.6kMr. Scott B. Brown CPA (Age 43)M.S., Chief Financial Officer Compensation: $403.1kDr. James L. Freddo M.D. (Age 69)Chief Medical Officer Mr. Ya HuangExecutive Director of Statistical Programming More Insider Trading Tools from MarketBeat Related Companies Aditxt Insider Buying Sorrento Therapeutics Insider Buying TFF Pharmaceuticals Insider Buying TC Biopharm Insider Buying Hepion Pharmaceuticals Insider Buying Smart for Life Insider Buying Evelo Biosciences Insider Buying Comera Life Sciences Insider Buying Genocea Biosciences Insider Buying eFFECTOR Therapeutics Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles NVIDIA Insiders Sell: This Is What It Means for the Market Top 3 Insider Stock Buys in March—Are They Still Good in April?Grocery Outlet Insider and Institutional Buyers Signal BottomSentinelOne Insider Selling? Why Investors Should Stay Bullish 3 Companies Buying Back Stock—Why It Matters This page (NASDAQ:TCON) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TRACON Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TRACON Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.